首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1534251

全球泌尿生殖藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Genitourinary Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球泌尿生殖藥物市場需求預計將從 2023 年的 352.3 億美元達到近 412.2 億美元的市場規模，2024-2032 年研究期間複合年成長率為 1.76%。

泌尿生殖藥物是一種旨在治療影響泌尿道和生殖器官的失調和疾病的藥劑。這些藥物涵蓋各種治療類別，包括抗生素、抗病毒藥物、抗真菌藥物、荷爾蒙和免疫抑制劑。它們用於治療泌尿道感染（UTI）、勃起功能障礙、良性前列腺增生（BPH）、不孕症、性傳染感染（STI）和各種泌尿生殖系統癌症等疾病。根據所治療的疾病或病症，這些藥物可能針對病原體、調節荷爾蒙水平、減少發炎或抑制癌細胞生長。

市場動態

泌尿生殖藥物市場是由泌尿生殖疾病盛行率不斷上升、藥物開發的進步以及不斷變化的醫療保健人口統計所推動的。泌尿道感染、攝護腺疾病和性傳染病等泌尿生殖系統疾病的發生率不斷上升，推動了對有效藥物治療的需求。快速的都市化、生活方式的改變和人口老化導致疾病負擔增加，需要泌尿生殖藥物療法的持續創新。此外，藥物輸送系統、個人化醫療方法和生物標記識別的進步提高了治療效果和患者結果。針對前列腺癌和勃起功能障礙等疾病的標靶治療正在擴大治療選擇並改善受影響個體的生活品質。此外，不斷成長的醫療保健支出和泌尿外科研究投資推動了市場擴張。製藥公司專注於開發新療法並擴大現有藥物的適應症，以滿足泌尿生殖醫學中未滿足的醫療需求。提高生殖健康意識、主動篩檢措施和病患教育計畫也促進泌尿生殖藥物市場的成長。醫療保健提供者和政策制定者優先考慮預防保健和早期干預策略，以支持泌尿生殖藥物的市場吸收。然而，藥品核准和專利到期的嚴格監管要求對市場成長提出了挑戰。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球泌尿生殖藥物市場的各個細分市場進行了包容性評估。泌尿生殖藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

泌尿生殖藥物市場報告的這一部分提供了有關國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按指示

攝護腺癌
卵巢癌
膀胱癌
子宮頸癌
腎癌
性功能障礙
泌尿道感染
尿失禁和膀胱過動症
性傳染病
間質性膀胱炎
血尿
良性攝護腺增生

按產品分類

泌尿科
荷爾蒙療法
婦科
抗感染藥
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲泌尿生殖藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。泌尿生殖藥物市場的主要參與者包括雅培、百時美施貴寶公司、諾華公司、基因泰克公司、F.霍夫曼-拉羅氏有限公司、Ionis Pharmaceuticals Inc.、禮來公司、默克公司、輝瑞公司、阿斯特捷利康、葛蘭素史克、梯瓦製藥工業有限公司、拜耳公司、艾爾建、Antares Pharma。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：泌尿生殖藥品公司的競爭格局

泌尿生殖藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Abbott

公司概況
公司收入
產品
最新動態

Bristol-Myers Squibb Co.

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

Genentech Inc.

公司概況
公司收入
產品
最新動態

F. Hoffmann-La RocheLtd.

公司概況
公司收入
產品
最新動態

Ionis Pharmaceuticals Inc.

公司概況
公司收入
產品
最新動態

Eli Lilly And Company

公司概況
公司收入
產品
最新動態

Merck & Co. Inc.

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

AstraZeneca

公司概況
公司收入
產品
最新動態

GlaxoSmithKline

公司概況
公司收入
產品
最新動態

Teva Pharmaceutical Industries Ltd.

公司概況
公司收入
產品
最新動態

Bayer AG

公司概況
公司收入
產品
最新動態

Allergan

公司概況
公司收入
產品
最新動態

Antares Pharma

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112115297

The global demand for Genitourinary Drugs Market is presumed to reach the market size of nearly USD 41.22 Billion by 2032 from USD 35.23 Billion in 2023 with a CAGR of 1.76% under the study period 2024-2032.

Genitourinary drugs are pharmaceutical agents designed to treat disorders & diseases affecting the urinary tract and reproductive organs. These drugs encompass various therapeutic categories, including antibiotics, antivirals, antifungals, hormones, and immunosuppressants. They are used to manage conditions such as urinary tract infections (UTIs), erectile dysfunction, benign prostatic hyperplasia (BPH), infertility, sexually transmitted infections (STIs), and various cancers of the genitourinary system. Based on the disease or disorder being treated, these drugs may target pathogens, modulate hormone levels, reduce inflammation, or inhibit cancer cell growth.

MARKET DYNAMICS

The genitourinary drugs market is driven by the increasing prevalence of genitourinary disorders, advancements in drug development, and evolving healthcare demographics. The rising incidence of genitourinary conditions such as UTIs, prostate disorders, and sexually transmitted diseases propels the demand for effective pharmaceutical treatments. Rapid urbanization, lifestyle changes, and aging populations contribute to a higher disease burden, necessitating continuous innovation in genitourinary drug therapies. Moreover, advancements in drug delivery systems, personalized medicine approaches, and biomarker identification enhance treatment efficacy and patient outcomes. Targeted therapies for conditions like prostate cancer and erectile dysfunction are expanding treatment options and improving the quality of life for affected individuals. Furthermore, growing healthcare expenditure and investments in urological research drive market expansion. Pharmaceutical companies focus on developing novel therapies & expanding indications for existing drugs to address unmet medical needs in genitourinary medicine. Increasing awareness about reproductive health, proactive screening initiatives, and patient education programs also foster genitourinary drugs market growth. Healthcare providers and policymakers prioritize preventive care and early intervention strategies, supporting market uptake of genitourinary drugs. However, stringent regulatory requirements for drug approval and patent expirations challenge market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Genitourinary Drugs. The growth and trends of Genitourinary Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Genitourinary Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

Prostate Cancer
Ovarian Cancer
Bladder Cancer
Cervical Cancer
Renal Cancer
Erectile Dysfunction
Urinary Tract Infections
Urinary Incontinence & Overactive Bladder
Sexually Transmitted Diseases
Interstitial Cystitis
Haematuria
Benign Prostatic Hyperplasia

By Product

Urologicals
Hormonal Therapy
Gynecological
Anti-Infectives
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Genitourinary Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genitourinary Drugs market include Abbott, Bristol-Myers Squibb Co., Novartis AG, Genentech Inc., F. Hoffmann-La RocheLtd., Ionis Pharmaceuticals Inc., Eli Lilly And Company, Merck & Co. Inc., Pfizer Inc., AstraZeneca, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Bayer AG, Allergan, Antares Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. GENITOURINARY DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Indication
- 3.7.2 Market Attractiveness Analysis By Product
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY INDICATION

5.1. Overview By Indication
5.2. Historical and Forecast Data Analysis By Indication
5.3. Prostate Cancer Historic and Forecast Sales By Regions
5.4. Ovarian Cancer Historic and Forecast Sales By Regions
5.5. Bladder Cancer Historic and Forecast Sales By Regions
5.6. Cervical Cancer Historic and Forecast Sales By Regions
5.7. Renal Cancer Historic and Forecast Sales By Regions
5.8. Erectile Dysfunction Historic and Forecast Sales By Regions
5.9. Urinary Tract Infections Historic and Forecast Sales By Regions
5.10. Urinary Incontinence & Overactive Bladder Historic and Forecast Sales By Regions
5.11. Sexually Transmitted Diseases Historic and Forecast Sales By Regions
5.12. Interstitial Cystitis Historic and Forecast Sales By Regions
5.13. Haematuria Historic and Forecast Sales By Regions
5.14. Benign Prostatic Hyperplasia Historic and Forecast Sales By Regions

6. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY PRODUCT

6.1. Overview By Product
6.2. Historical and Forecast Data Analysis By Product
6.3. Urologicals Historic and Forecast Sales By Regions
6.4. Hormonal Therapy Historic and Forecast Sales By Regions
6.5. Gynecological Historic and Forecast Sales By Regions
6.6. Anti-Infectives Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE GENITOURINARY DRUGS COMPANIES

8.1. Genitourinary Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF GENITOURINARY DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Abbott
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Bristol-Myers Squibb Co.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Novartis AG
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Genentech Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. F. Hoffmann-La RocheLtd.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Ionis Pharmaceuticals Inc.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Eli Lilly And Company
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Merck & Co. Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Pfizer Inc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. AstraZeneca
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments
9.13. GlaxoSmithKline
- 9.13.1 Company Overview
- 9.13.2 Company Revenue
- 9.13.3 Products
- 9.13.4 Recent Developments
9.14. Teva Pharmaceutical Industries Ltd.
- 9.14.1 Company Overview
- 9.14.2 Company Revenue
- 9.14.3 Products
- 9.14.4 Recent Developments
9.15. Bayer AG
- 9.15.1 Company Overview
- 9.15.2 Company Revenue
- 9.15.3 Products
- 9.15.4 Recent Developments
9.16. Allergan
- 9.16.1 Company Overview
- 9.16.2 Company Revenue
- 9.16.3 Products
- 9.16.4 Recent Developments
9.17. Antares Pharma
- 9.17.1 Company Overview
- 9.17.2 Company Revenue
- 9.17.3 Products
- 9.17.4 Recent Developments